Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Conditions
Hepatocellular Carcinoma · Biliary Tract Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beverly Hills Cancer Center, Beverly Hills, California, United States
Contact: Study coordinator (Afshin Eli Gabayan, MD)UC San Diego Moores Cancer Center, La Jolla, California, United States
Contact: Study coordinator (Adam Burgoyne, MD)Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami, Florida, United States
Contact: Study coordinator (Lynn Goy Feun, MD)Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Richard Kim, MD)University of Maryland Medical Center, Baltimore, Maryland, United States
Contact: Study coordinator (Kevin"Hyun" Kim, MD)Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Contact: Study coordinator (Renuka Iyer, MD)Montefiore Medical CenterMontefiore Medical Park, The Bronx, New York, United States
Contact: Study coordinator (Yvonne Saenger,, MD)University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (William Chapin, MD)UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Anwaar Saeed, MD.)The West Clinic, Germantown, Tennessee, United States
Contact: Study coordinator (Axel Grothey, MD)University of Tennessee Medical Center, Knoxville, Tennessee, United States
Contact: Study coordinator (Saikrishna Gadde, MD)Houston Methodist Hospital Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Maen Abdelrahim, MD)
Study leads
Gary Vanasse, MD
Study Director
Replimune, Inc.